Menu Close

Diffuse Intrinsic Pontine Glioma (DIPG)

Other names for DIPG include diffuse midline glioma (DMG), H3 K27M-mutant.

What is DIPG?

Diffuse intrinsic pontine glioma, or DIPG, is an aggressive brain tumor. It forms in the base of the brain. DIPG begins in the brain stem. The area is called the pons.

The pons controls vital life functions including:

  • Breathing
  • Heart rate
  • Blood pressure

Nerves that control vision, hearing, speech, swallowing, balance, and movement also pass through this part of the brain.

Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain tumor. It begins in the brainstem in an area called the pons. The pons controls vital life functions as well as the nerves that control vision, hearing, speech, swallowing, and movement.

Diffuse intrinsic pontine glioma (DIPG) is an aggressive brain tumor. It begins in the brainstem in an area called the pons. The pons controls vital life functions as well as the nerves that control vision, hearing, speech, swallowing, and movement.

About 200–300 new cases of DIPG are diagnosed every year in the United States. DIPG most often occurs in children ages 5–10 years old. But it can occur in younger children and teens. DIPG is rare in adults.

DIPG is a type of high-grade glioma. It grows from glial cells that make up the supportive tissue of the brain. DIPG is a diffuse tumor. This means it is not well-defined or contained. The tumor extends finger-like projections into healthy tissue.

Because of the location and spread-out growth of the tumor, surgery cannot safely remove DIPG.

DIPG is very hard to treat and there is no cure. Most children do not survive more than 2 years after diagnosis. The main treatment for DIPG is radiation therapy. Radiation temporarily improves symptoms in most patients, but it is not a cure. Families may consider clinical trials that test new treatments to see if outcomes can be improved.

Early palliative care is important. It can help families manage symptoms and promote quality of life.

DIPG is an older term for a type of diffuse midline glioma found in the pons. It is also known as diffuse midline glioma (DMG), H3 K27M-altered, H3 K27-altered DMG, or brainstem glioma.

Symptoms of DIPG

DIPG tumors grow quickly. Symptoms usually develop in a short period of time (often about 1 month before diagnosis). There is a rapid onset and fast progression.

Signs and symptoms of DIPG may include:

  • Loss of balance or problems walking
  • Eye problems such as blurred vision, double vision, drooping eyelids, uncontrolled eye movements, not being able to fully close the eye, eyes don’t look the same direction together or appear crossed (strabismus)
  • Facial weakness or drooping, usually on 1 side
  • Drooling or problems swallowing
  • Weakness in the legs and arms, usually on 1 side
  • Irregular or jerking movements
  • Abnormal reflexes
  • In very young children, a failure to thrive

Less common symptoms may include:

  • Nausea and vomiting
  • Headache, especially in the morning and often better after vomiting
  • Behavioral changes, school problems, irritability, or night laughter

  1. Read more: Nerve problems and signs of DIPG

    Nerve problems: Cranial nerves are 12 pairs of nerves that arise in the brain. Cranial nerves 5, 6, and 7 arise in the pons. They can be affected in DIPG. Specific problems can be related to each of these nerves:

    • Cranial nerve 5: Loss of sensation or numbness over the face and parts of the mouth
    • Cranial nerve 6: Abnormal eye movements, such as not being able to look to the side or crossing of the eye
    • Cranial nerve 7: Weakness over the face, mainly the mouth and eyelids

    Problems with cranial nerves 6 and 7 are most common in DIPG. Sometimes other cranial nerves can be injured and cause other symptoms.

    DIPG triad: Because of where the tumor is located, children with DIPG often have a collection of 3 symptoms, sometimes known as the DIPG triad of symptoms. Most patients develop at least 1 of these signs:

    1. Problems with balance and coordination (ataxia)
    2. Weakness in the arms and legs, jerking movements, and abnormal reflexes 
    3. Facial weakness or drooping or abnormal eye movement due to problems with nerves that control the muscles and sensation of the head, face, and eyes 

    About 1 in 3 patients have all 3 signs at diagnosis. 

Diagnosis of DIPG

An MRI can be used to diagnose diffuse intrinsic pontine glioma.

An MRI can be used to diagnose diffuse intrinsic pontine glioma.

Tests to diagnose DIPG include:
  • A physical exam and medical history help doctors learn about symptoms, general health, past illness, and risk factors.
  • A neurological exam measures different aspects of brain function. These include memory, vision, hearing, muscle strength, balance, coordination, and reflexes.
  • Imaging tests help identify the tumor, see how big the tumor is, and find out what brain areas may be affected. Magnetic resonance imaging (MRI) is the main imaging test used to diagnose DIPG.

Doctors look for key features of the tumor on the MRI to diagnose DIPG:

  • The tumor is in the pons.
  • It usually involves and expands most of the pons (intrinsic).
  • The tumor does not have well-defined borders. It moves into healthy tissue (diffuse).

About 10–20% of pediatric brain tumors are found in the brain stem. A tumor in the brain stem is usually DIPG. But about 20% (2 out of 10) of brain stem tumors are low-grade astrocytomas. These are not considered DIPG.

Role of biopsy in DIPG diagnosis

Doctors sometimes use a biopsy to diagnose DIPG. In the past, a biopsy was not usually done. Reasons for not doing a biopsy include:

  • DIPG often has specific features on MRI and clinical evaluation. This means it can be diagnosed without any more tests.
  • There is risk of harm from a biopsy. This is because of the tumor’s location.
  • A biopsy may not change treatment plans or outcomes.

Because of advances in surgery and treatments, biopsy has become more common for DIPG. After a biopsy, a pathologist looks at the tissue sample under a microscope to identify the type and grade of tumor. The tumor is tested for genetic changes or markers. Understanding molecular features may one day offer better treatments for DIPG. These could include targeted therapy and immunotherapy.

Diffuse midline glioma, H3 K27M-mutant: About 80% (8 out of 10) of DIPG tumors have a specific mutation, or change in the DNA. This mutation is known as H3 K27M. These tumors most often occur in the pons. But they may also be found in the thalamus, spinal cord, or other sites in the midline of the brain. Even without a biopsy, it is thought that most DIPG tumors have the H3 K27M mutation. Tumors with an H3 K27M mutation usually have a poor outcome no matter the grade or how they appear under the microscope.

No one knows the cause of DIPG. But scientists are learning more about gene changes linked to these tumors. Having certain genetic disorders, including neurofibromatosis type 1 (NF1), may increase the risk of a brain stem glioma.

Staging and grading of DIPG

There is no standard staging system for DIPG. Treatment is based on 2 main factors:

  1. Whether DIPG is found only in the brain stem or if it has spread to distant areas in the brain or spinal cord (metastatic disease)
  2. Whether DIPG is newly diagnosed or has come back after treatment (recurrent disease)

Gliomas are grouped by how they look under the microscope. The more abnormal the cells look, the higher the grade. Grade 1 and 2 tumors are low-grade gliomas. The cells look more like normal cells and grow more slowly.

Grade 3 and 4 tumors are high-grade gliomas. They are aggressive and grow quickly. These tumors can spread throughout the brain.

DIPG tumors are usually high-grade. Rarely, DIPG may appear as a low-grade tumor (grade 2).

Treatment of DIPG

DIPG is fast growing. No cure is known at this time. The standard of care is based on radiation therapy.

Much of DIPG patient care focuses on controlling symptoms and supporting quality of life. Corticosteroid medicines such as dexamethasone can help reduce some of the tumor’s symptoms. These medicines are usually used at diagnosis and at tumor progression to help manage neurologic symptoms.

A number of clinical trials are exploring therapies that may improve outcomes for patients with DIPG.

  1. Radiation therapy for DIPG

    Radiation therapy is the main treatment for DIPG. In most cases, radiation provides a temporary response to slow or shrink the tumor. But radiation therapy does not provide a long-term cure. It may ease symptoms for an average of 6 months. It may extend life by an average of 3 months.

    At most U.S. treatment centers, the standard guideline is local radiation therapy for 6–7 weeks.

    Newer studies suggest that hypofractionated radiation therapy may offer similar benefits with less burden on the patient and family. This approach gives larger doses of radiation over a shorter time (usually 3 weeks).

    Radiation usually helps stall disease progression for a time. Recent studies have shown that repeat radiation to the DIPG tumor can be done safely. But when the disease comes back, the tumor is more resistant to radiation, and the benefits are more limited. When radiation is given a second time, it is usually done over 2–3 weeks.

  2. Chemotherapy for DIPG

    Chemotherapy may be used along with radiation therapy for DIPG. But it does not increase the length of life or overall survival. In general, chemotherapy is not offered as part of standard care for DIPG.

    More tumor-specific treatment protocols for DIPG are being tested through clinical trials. These include different combinations of drugs and new methods of giving them.

  3. Surgery for DIPG

    DIPG is impossible to remove with surgery. The area of the brain where the tumor occurs controls vital life functions. This means the tumor cannot be removed by surgery.

    Surgery may be used to help treat hydrocephalus. As the pons expands due to tumor, it can block cerebrospinal fluid (CSF) around the brain and spinal cord. This can cause added pressure on the brain. A child with hydrocephalus may have a shunt placed to drain fluid from the brain.

  4. Targeted therapy for DIPG

    Targeted therapies work by targeting specific features of the tumor such as genes and proteins. Some targeted therapies being studied as part of clinical trials for DIPG target:

    • Cell surface receptors thought to be enriched or active in DIPG
    • Intracellular proteins that control cell growth and survival of tumor cells
    • Proteins that repair DNA damage that might be changed in DIPG, making cancer cells more resistant to radiation and chemotherapy
    • Proteins that control gene expression related to the H3 K27M mutation

  5. Immunotherapy for DIPG

    Immunotherapy is a type of treatment that uses the body’s own immune system to recognize and attack cancer cells.

    Certain types of immunotherapy are being explored in patients with DIPG. These include antibodies that may activate the patient’s immune system to fight the DIPG tumor. Scientists are also studying whether a vaccine may be able to target DIPG tumor cells that have a certain type of H3 K27M mutation.

Many patients with DIPG get care through a clinical trial. Clinical trials are available:

  • At the time of diagnosis
  • After completion of radiation therapy but before the disease progresses
  • After tumor progression

Many times, the tumor may shrink for a while after initial radiation therapy. Symptoms improve, and patients can go home to their usual activities. This is sometimes called the “honeymoon period.”

This phase is hard to predict. Some children are almost back to normal during this time. Some children do not improve at all. Families may use the time to be together or do something special as a family. Wish-granting organizations can often help with this.

Prognosis for DIPG

DIPG has no cure at this time. Fewer than 10% (1 out of 10) of children in the United States survive more than 2 years after diagnosis. A somewhat better outcome may be seen in very young patients (3 years old or younger) and those who have symptoms for a longer time before diagnosis.

Long-term survival in DIPG is generally linked to unusual tumor features or a misdiagnosis in which the tumor was not actually DIPG.

Early palliative care is important to help manage symptoms and provide support in making treatment decisions.

Support for children with DIPG

In DIPG, symptoms get worse over time. Supportive care helps maintain quality of life as much as possible for as long as possible. Talk to your care team about problems to expect and ways to help manage them.

Common symptoms of late stage DIPG

Symptoms can worsen rapidly when DIPG comes back. But symptoms and their course and severity can vary.

Some signs and symptoms of late-stage DIPG include:

  • Loss of balance and motor control. This often leads to inability to walk and the need for a wheelchair.
  • Weakness and paralysis that gets worse, often on 1 side of the body
  • Problems swallowing. This may lead to aspiration pneumonia, not being able to eat normally, and requiring a feeding tube
  • Weight gain and face swelling or puffiness because of corticosteroid medicines such as dexamethasone
  • Problems speaking or communicating
  • Anxiety, irritability, or agitation
  • Depression and feelings of sadness
  • Fatigue or drowsiness
  • Sleep problems
  • Changes in vision
  • Headache
  • Nausea and vomiting
  • Constipation
  • Decrease in urine, urinary retention
  • Problems breathing
  • Problems with heart rate and blood pressure
  • Seizures
  • Confusion, delirium
  • Loss of consciousness

Medicines can help control pain, nausea and vomiting, anxiety and depression, and medical problems that develop as the tumor grows.

Art therapy, music therapy, and other complementary therapies can also help patients and families manage symptoms.

Weight gain and face swelling with DIPG

Weight gain, face swelling, and puffiness are mainly due to high doses of corticosteroid medicines given to help manage symptoms of DIPG. These symptoms are not usually due to the tumor itself.

Brain tumors can cause fluid and pressure to build up in the brain (hydrocephalus). This pressure causes symptoms such as headaches, nausea, weakness, and problems walking. Steroid medicines like dexamethasone decrease brain swelling and pressure. But they also have side effects, especially when given in high doses or for a long time.

Corticosteroids can increase appetite and cause patients to eat more and gain weight. These medicines can make it hard for the body to get rid of fluids, causing swelling. The body may also store fat differently. This can lead to puffy cheeks or “moon face.”

Rapid weight gain sometimes causes stretch marks on the skin. The change in appearance due to corticosteroids can be distressing to patients and families. Other side effects of steroid treatment include mood swings, irritability, and muscle weakness.

Despite the side effects, these medicines are an important part of supportive care and quality of life for many brain tumor patients. Talk to your care team about side effects and goals of care.

Read more about steroids from the American Brain Tumor Association.

Working with your care team

With the poor prognosis of DIPG, it is important for families to talk with their care teams about goals of therapy, palliative care, and end of life care. These conversations should begin early in the care process.

Goals of care change over the course of the disease with the changing needs of the patient and family.

A team of health care providers can help meet specific patient needs as DIPG progresses.

Palliative care or quality of life services help patients and families:

  • Manage pain and other symptoms
  • Promote quality of life
  • Make difficult decisions including treatment choices and end of life care 

Hospice care provides medical and practical support as patients near the end of life. Rehabilitation services provide care for movement, speech, hearing, or swallowing problems. Child life, social work, spiritual care, and psychology can help with emotional and practical needs through the cancer journey for the entire family.

Questions to ask your care team

  • What are the treatment options for DIPG?
  • Should we consider a clinical trial for DIPG?
  • What can we expect as my child’s illness progresses?
  • When should we involve the palliative care team?
  • What can be done to manage symptoms and side effects?
  • What supportive care options can help with comfort and quality of life?

Key points about DIPG

  • DIPG is an aggressive brain tumor that forms in the pons, a structure located in the brain stem.
  • DIPG is hard to treat, and there is no cure. 
  • Radiation therapy is one of the most common treatments.
  • Most children do not survive more than 2 years after diagnosis of DIPG.
  • DIPG symptoms can progress quickly. They can include loss of balance and motor skills, headaches, weight gain, and difficulty swallowing.
  • Early support from the palliative care team can help families manage symptoms and make care and treatment decisions.

Find more information  

—
Reviewed: July 2025

Related Content

  • Steroid Medicines and Behavior

    Steroid medicines can change your child’s behavior, emotions, and thoughts. Learn about mood and behavioral side effects of steroids and how to help your child.

  • Palliative Care

    Pediatric palliative care is an approach to care for children facing a serious illness. Learn how the pediatric palliative care team can help.

  • Clinical Trials

    A clinical trial is a research study to test new ways to treat or prevent diseases and health problems. Learn how to enroll in clinical trials.